Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

MRI

Drug and asset intelligence for MRI with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Stage: Development stage unavailable

Recent signals(2)

ClinicalJuly 19, 2026

Cost-effectiveness of MRI and PET/CT in Prostate Cancer Staging Reevaluated with New Phase 3 Data

Recent Phase 3 trials have provided updated data on the cost-effectiveness of ferumoxtran-enhanced MRI and PSMA-PET/CT compared to ePLND for nodal staging in prostate cancer.

ClinicalJuly 13, 2026

MRI and Multiomics Integration for Precision Treatment in Luminal Breast Cancer

A study is underway to integrate MRI and multiomics data for non-invasive molecular typing in luminal breast cancer.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Breast Cancer →

Prostate Cancer →

Therapeutic areas

Breast Cancer →

Prostate Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.